International Journal of Physiology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Effect of Artesunate on Electrocardiographic Qt Interval in Patients with Plasmodium Falciparum Malaria


Affiliations
1 Demonstrator, Department of Biochemistry, Chhattisgarh Institute of Medical Sciences, Bilaspur (C.G.), India
     

   Subscribe/Renew Journal


Background: Several anti-malarial drugs are associated with adverse cardiovascular effects. There are a few reports available on the potential cardiac effects ( QTc interval) of artesunate, which includes an increased risk of potentially ventricular arrhythmia. This study aimed to evaluate the electrocardiographic (ECG) Changes (QTc interval ) in malaria patients treated with artesunate.

Method: Total 32 (16 male&16 female ) patients with severe Falciparum malaria enrolled in medical ward, CIMS hospital Bilaspur (C.G) were selected. Electrocardiogram was recorded, and QTc interval was calculated before and after administration of three doses of artesunate given by intravenous injection in all patients who were positive for Falciparum malaria.

Results: The mean QTc interval was not affected by intravenous artesunate (2.4 mg/kg) given at different time intervals(p>0.05). There was no significant effect observed on the JTc or PR interval, QRS width, blood pressure and heart rate. Intravenous artesunate does not have significant other cardiovascular effects in patients with severe Falciparum malaria.

Conclusion: Intravenous artesunate does not have significant cardiovascular effects in patients with falciparum malaria.

 


Keywords

QT Interval, Plasmodium Falciparum, Artesunate
Subscription Login to verify subscription
User
Notifications
Font Size


  • World Health Organization Global Malaria Programme. WHO Guidelines for the Treatment of Malaria. 2008. http://www.who.int/malaria/ docs/TreatmentGuidelines2006.pdf . Accessed April 15 2013.

  • Dondorp A, Nosten F, Stepniewska K, Day N. White N et al. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT). Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–725.

  • White NJ. Cardiotoxicity of antimalarial drugs. Lancet. 2007;7:549–558.

  • Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993; 341:1054–1056.

  • Sanguinetti MC, Jurkioewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195–215.

  • International Conference on Harmonization The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. ICH Harmonized Tripartite Guideline. 2008. http://www.ich.org/ LOB/media/MEDIA1476.pdf . Accessed June 15 2013.

  • Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf. 2005;28: 1009–1028.

  • Owens RC, Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43:1603–1611.

  • Classen W, Altmann B, Gretener P, Souppart C, Skelton-Stroud P, Krinke G. Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs. Exp Toxicol Pathol.1999;51:507–516.

  • Tran TH, Day NP, Nguyen HP, Nguyen TH, Tran TH, Pham PL, Dinh XS, Ly VC, Ha V, Waller D, Peto TE, White NJ. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335: 76–83.

  • Bazett HC. An analysis of the time-relations electrocardiograms. Heart. 1920;7:353–370.

  • George OA, Collins OB, Onike P R, Lotte C H, Michael A, Jorgen A K, Bamenla QG. Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate amodiaquine or artemetherlumefantrine. Malaria Journal 2012 11:420.

  • Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med.2003;348:1866–1874.

  • van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatna P, Looareesuwan S, White NJ. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg.1999;61:964–967.

  • White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med. 1982;73:564–572.

  • Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, Heiffer MH, Schuster BG. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg. 1994;51:251–259.

  • Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, De Palacios PI. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicatedPlasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg.2006;74:991–998.

  • van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol. 1999;55:405–410.

  • Kshirsagar NA, Gogtay NJ, Moorthy NS, Garg MR, Dalvi SS, Chogle AR, Sorabjee JS, Marathe SN, Tilve GH, Bhatt AD, Sane SP, Mull R, Gathmann I. A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral coartemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am J Trop Med Hyg. 2000;62:402–408.

  • Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, Davis TM. Safetly evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.Br J Clin Pharmacol. 2004;57:93–99.

  • Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, White NJ. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. Am J Trop Med Hyg. 1998;59:519–522.

  • Nontprasert A, Pukrittayakamee S, Nosten- Bertrand M, Vanijanonta S, White NJ. Studies of the neurotoxicity of oral artemisinin derivatives in mice. Am J Trop Med Hyg. 2000;62:409–412.

  • Zhao Y. Studies on systemic pharmacological effects of artesunate. Am J Trop Med Hyg. 1985;88:391–396.

  • Qichao Y, Weizhi S, Rei L, Jun G. The antimalarial and toxic effect of artesunate in animal models. J Tradit Chin Med. 1982;2:99–103.


Abstract Views: 494

PDF Views: 0




  • Effect of Artesunate on Electrocardiographic Qt Interval in Patients with Plasmodium Falciparum Malaria

Abstract Views: 494  |  PDF Views: 0

Authors

Singh Lakhan
Demonstrator, Department of Biochemistry, Chhattisgarh Institute of Medical Sciences, Bilaspur (C.G.), India
Jain Lalit
Demonstrator, Department of Biochemistry, Chhattisgarh Institute of Medical Sciences, Bilaspur (C.G.), India
Singh Hemlata
Demonstrator, Department of Biochemistry, Chhattisgarh Institute of Medical Sciences, Bilaspur (C.G.), India
Nigam Prashant
Demonstrator, Department of Biochemistry, Chhattisgarh Institute of Medical Sciences, Bilaspur (C.G.), India

Abstract


Background: Several anti-malarial drugs are associated with adverse cardiovascular effects. There are a few reports available on the potential cardiac effects ( QTc interval) of artesunate, which includes an increased risk of potentially ventricular arrhythmia. This study aimed to evaluate the electrocardiographic (ECG) Changes (QTc interval ) in malaria patients treated with artesunate.

Method: Total 32 (16 male&16 female ) patients with severe Falciparum malaria enrolled in medical ward, CIMS hospital Bilaspur (C.G) were selected. Electrocardiogram was recorded, and QTc interval was calculated before and after administration of three doses of artesunate given by intravenous injection in all patients who were positive for Falciparum malaria.

Results: The mean QTc interval was not affected by intravenous artesunate (2.4 mg/kg) given at different time intervals(p>0.05). There was no significant effect observed on the JTc or PR interval, QRS width, blood pressure and heart rate. Intravenous artesunate does not have significant other cardiovascular effects in patients with severe Falciparum malaria.

Conclusion: Intravenous artesunate does not have significant cardiovascular effects in patients with falciparum malaria.

 


Keywords


QT Interval, Plasmodium Falciparum, Artesunate

References